

# Antihyperlipidemic Drugs Market to Garner \$16.86 Bn by 2026 | CAGR 7.5%

*Presence of guidelines recommending the use of statins, rise in prevalence of hyperlipidemia across world & surge in healthcare expenditure are boost the market*

PORTLAND, OR, UNITED STATES, October 14, 2020 /EINPresswire.com/ -- According to the report, the global [antihyperlipidemic drug industry](#) was pegged at \$9.46 billion in 2019 and is projected to reach \$16.86 billion by 2026, registering a CAGR of 7.5% from 2019 to 2026.

Incentives for market growth

Presence of guidelines recommending the use of statins, rise in prevalence of hyperlipidemia across the globe, and surge in healthcare expenditure have boosted the global antihyperlipidemic drug market. However, upcoming patent expiration of drugs hampers the market growth. On the contrary, high growth potential in developing economies is expected to create lucrative opportunities in the near future.

Request Sample Report at: <https://www.alliedmarketresearch.com/request-sample/6284>

Statins segment dominated the market

The statins segment held the largest share in 2018, contributing to nearly two-fifths of the market, owing to surge in the incidence of cardiovascular disorders and its ability to reduce the risk associated with heart attacks. However, the PCSK9 inhibitors segment is projected to register the fastest CAGR of 9.7% during the forecast period, owing to benefits offered such as drastic reduction of LDL levels in the blood.

North America region held the largest share



The market across North America held the largest share in 2018, accounted for nearly one-third of the market, owing easy availability of the antihyperlipidemic drugs and sedentary lifestyle in the region. On the contrary, Asia-Pacific region is expected to register the fastest CAGR of 8.6% from 2019 to 2026, owing to surge in awareness related to the use of antihyperlipidemic drugs and surge in the healthcare expenditure.

Major market player

Boehringer Ingelheim GmbH

Merck KGaA

Johnson and Johnson

Bayer AG

Pfizer, Inc.

Takeda Pharmaceutical Co., Ltd.

AstraZeneca plc

Daiichi Sankyo Company

Sanofi S.A.

Novartis International AG

For Purchase Enquiry at: <https://www.alliedmarketresearch.com/purchase-enquiry/6284>

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at \$699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying:

<https://www.alliedmarketresearch.com/avenue/trial/starter>

Get more information: <https://www.alliedmarketresearch.com/library-access>

Similar Reports:

[Anti-Rheumatics Market](#): Global Opportunity Analysis and Industry Forecast, 2019–2026

[Antihypertensive Drugs Market](#): Global Opportunity Analysis and Industry Forecast, 2019–2026

David Correa

Allied Analytics LLP

800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/528381746>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.